Stem cell therapy for multiple sclerosis Background: Mesenchymal stem cells with their potential to differentiate into mesodermal and nonmesodermal ancestors have various immunomodulatory properties. These properties make them assuring tools in cell and gene therapeutics.
Objective: To assess the possible therapeutic uses of autologous MSC in developing clinical signs of MS patients.
Methods: Ten patients were involved in this guided study. All had a moving disease that had not reacted to disease-modifying agents including Mitoxantrone. Their Expanded Injury Status Scale score ranged from 3.5 to 6. Patients were implanted intrathecally with culture-expanded MSCs. They were succeeded with monthly neurological assessment and an MRI scans at the end of the first year.
Results: During 13 to 26 months of follow up, the EDSS of one patient improved from 5 to 2.5 score. Four patients showed no change in EDSS. Five patientsâ€™ EDSS increased from 0.5 to 2.5. In the practical system assessment, six patients showed some degree of change in their sensible, pyramidal, and cerebellar functions. One showed no difference in clinical evaluation and three declined. The result of the MRI assessment after 12 months was as follows: seven patients with no difference, two showed an additional plate, and one patient showed the reduction in the number of plaques. Conclusion: This previous report features the utility of autologous MSC for the treatment of MS patients. However, in order to draw a definitive judgment, a larger sample size is needed.
Regenerative Medicine New Jersey is the best Treatment all over the USA. You can consult our Doctor. Contact Us at (844) 438-3876